OBJECTIVES The serum tumor marker CA 125 is elevated in most clinically advanced ovarian carcinomas. Because these elevations may precede clinical detection by a year or more, CA 125 is potentially useful for early detection as part of an ovarian cancer screening program. However, CA 125 is often not elevated in clinically detected cancer and is frequently elevated in women with benign ovarian ...

The aim of this study was to investigate cycle dependent changes of serum CA 125 and CA 15-3 concentrations during spontaneous ovulatory cycles. Twenty apparently healthy women with spontaneous menstrual cycles attending our infertility clinic were included. Of these women, 18 had occluded tubes as a result of sterilization. Ovulation was confirmed by luteinizing hormone test and ultrasonograph...

background: b-cell non-hodgkin’s lymphoma (nhl) is a common malignancy of lymphoid tissues. different types of nhl show various behaviors, prognoses, and responses to treatment. evaluation of disease activity in nhl can be helpful in managing and even increasing the patient’s survey. methods and results: in total, 121 patients (76 males and 45 females), and their age range were 18-53 years, wer...

Very high concentrations of CA 125 have been found in some ovarian cancer patients after repeated radioimmunodetection with anti-CA 125 antibodies [OC125-F(ab')2]. In one patient we measured a CA 125 concentration of 135,000 kilo-arb. units/L, using an enzyme immunoassay involving OC125 antibodies. With an immunoradiometric assay involving use of two new anti-CA 125 antibodies (B43.13 and B27.1...

CA-125 is a 220-kD cell surface glycoprotein present in over 80% of non-mucinous epithelial ovarian carcinomas and it occurs in the serum of healthy males and females at low concentrations (< 35 U/mL). Serum CA-125 concentration may also be moderately elevated in several benign conditions, such as pelvic inflammatory disease, uterine fibroids, pregnancy, spontaneous abortion with chromosomal ab...

Various authors (1,2) have tried to ascertain whether CA 125 concentrations in PF samples were significantly higher in patients with endometriosis than in control subjects. So far, these studies have not shown any significant difference in CA 125 values obtained from undiluted PF samples. In our study, using diluted samples in one-step assay, we found that CA 125 concentrations differed between...

BACKGROUND The aim of this study was to assess the prognostic value of cancer antigen (CA) 125 and CA 72-4 in patients with ovarian borderline tumor (BOT). METHODS All women diagnosed and treated for BOT at our institution between 1981 and 2008 were included into this retrospective study (n=101). Preoperatively collected serum samples were analyzed for CA 125 (Architect, Abbott and Elecsys, R...

of death from gynaecological cancer among women in Western countries. Epithelial ovarian cancer is responsible for 85-90% of all primary ovarian tumours. Because of the asymptomatic nature of the disease, ovarian cancer is usually not detected in the early stages and therefore many women present with advanced disease and systemic metastases. Approximately 70-80% of patients present with late st...